Patents Represented by Attorney, Agent or Law Firm Peter L. Dolan
-
Patent number: 6641063Abstract: The invention is an improved method of generating fine medicament powders suitable for inhalation. A fluid energy mill is used with conventional milling fluids such as air or nitrogen. The milling fluid is treated to have a controlled relative humidity of between 30% and 70%. This produces a fine medicament powder with a median particle size below 10 micrometer but with little or no amorphous content generated during milling. Scale formation in the mill chamber is also greatly reduced.Type: GrantFiled: June 1, 2001Date of Patent: November 4, 2003Assignee: Aventis Pharma LimitedInventors: Narasimha M. Vemuri, Andrew B. Brown, Jean-Rene Authelin, Patrik Hosek
-
Patent number: 6557550Abstract: An inhalation device which contains powdered medicament in the form of a medicament compact is provided with a seal comprising a partial ring between the outer wall and inner mandrel of the medicament compact chamber. The medicament is dispensed by abrading the medicament compact by turning the compact relative to the inner mandrel against a blade. Despite only extending around part of the circumference of the mandrel the seal prevents leakage of loose powder from the compact chamber to the rest of the device. The sealing means also provides a frictional braking force on the medicament reservoir sufficient to prevent movement of the medicament reservoir when the drive mechanism for the reservoir is returning to its starting position without making the device difficult to operate by a child or infirm adult.Type: GrantFiled: April 19, 2000Date of Patent: May 6, 2003Assignee: Aventis Pharma LimitedInventor: Alastair Robert Clarke
-
Patent number: 6524553Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.Type: GrantFiled: March 30, 1999Date of Patent: February 25, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Thomas David Harris
-
Patent number: 6511648Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: December 17, 1999Date of Patent: January 28, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Thomas D. Harris, Milind Rajopadhye
-
Patent number: 6511649Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: June 21, 2000Date of Patent: January 28, 2003Inventors: Thomas D. Harris, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye
-
Patent number: 6455024Abstract: Radiotherapy agents which are solid or porous particles are described. The particles are of an inorganic material containing a suitable radionuclide and having an average particle diameter of about 0.05 to 5000 microns.Type: GrantFiled: April 2, 1999Date of Patent: September 24, 2002Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Joseph L. Glajch, Prahlad R. Singh
-
Patent number: 6416733Abstract: The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.Type: GrantFiled: October 3, 1997Date of Patent: July 9, 2002Assignee: Bristol-Myers Squibb Pharma CompanyInventors: John A. Barrett, Edward H. Cheesman, Thomas D. Harris, Shuang Liu, Milind Rajopadhye, Michael Sworin
-
Patent number: 6403054Abstract: The present invention provides novel radiopharmaceuticals useful for imaging the heart, brain, lungs, liver or kidneys, kits useful for preparing the radiopharmaceuticals, and methods of imaging the heart, brain, lungs, liver or kidneys in a patient in need of such imaging. The radiopharmaceuticals are comprised of technetium or rhenium radionuclide complexes of a ternary ligand system: one hydrazido or diazenido ligand, one aminoalcohol ligand, and one pi-acid ligand selected from phosphines, arsines, and imine nitrogen-containing heterocycles. The radiopharmaceuticals have the formula, ML1L2L3, wherein the variables are as defined herein.Type: GrantFiled: May 28, 1997Date of Patent: June 11, 2002Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Shuang Liu
-
Patent number: 6391279Abstract: Novel radioactive seeds for brachytherapy and a reproducible method of manufacturing the seeds is described, wherein the seeds contain either Pd-103 or I-125 disposed within a cured resin matrix.Type: GrantFiled: November 13, 1998Date of Patent: May 21, 2002Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Prahlad R. Singh, Gerald P. Tercho, Jack N. Wentz, Keith R. Olewine
-
Patent number: 6362344Abstract: Chiral aminoalcohol catalysts and methods for their preparation are provided. The first catalyst is prepared via selective hydrogenation of one of two benzene rings in a precursor. The aminoalcohol promotes the asymmetric addition of organozinc reagents to aldehydes to afford optically active alcohols or their esters. The second catalyst is prepared by selective dialkylation of 3-exo-aminoisoborneol with a 2-haloethyl ether. The aminoalcohol promotes the addition of organozinc reagents to aliphatic aldehydes containing a &bgr;-branch with greatly enhanced enantioselectivity relative to DAIB.Type: GrantFiled: September 26, 2000Date of Patent: March 26, 2002Assignee: Bristol-Myers Squibb Pharma CompanyInventor: William A. Nugent
-
Patent number: 6362180Abstract: Corticotropin releasing factor (CRF) antagonists of formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.Type: GrantFiled: December 10, 1998Date of Patent: March 26, 2002Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Richard Gerald Wilde, Rajagopal Bakthavatchalam, James Peter Beck, Argyrios Georgious Arvanitis
-
Patent number: 6348504Abstract: This invention relates generally to oxime ethers which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.Type: GrantFiled: March 30, 1999Date of Patent: February 19, 2002Inventors: Richard E. Olson, William E. Frietze
-
Patent number: 6322770Abstract: The present invention d ribs novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.Type: GrantFiled: March 30, 1999Date of Patent: November 27, 2001Assignee: DuPont Pharmaceuticals CompanyInventors: Milind Rajopadhye, Thomas David Harris
-
Patent number: 6291504Abstract: The present invention relates to the synthesis of a new lass of indeno[1,2-c]pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.Type: GrantFiled: October 19, 2000Date of Patent: September 18, 2001Assignee: DuPont Pharmaceuticals CompanyInventors: David A. Nugiel, David J. Carini, Susan V. Di Meo, Anup P. Vidwans, Eddy W. Yue
-
Patent number: 6261231Abstract: The present invention relates to an apparatus for holding a probe and a method for using the same. The apparatus comprises a body portion having a longitudinal bore and a membrane holder positioned over a first end of the body portion. The membrane holder defines an opening which is covered by a membrane. A receptacle for receiving the probe is rotatably positioned within the longitudinal bore of the body portion at a second end of the body portion. The membrane, membrane holder, body portion, receptacle, and probe define a sealed chamber for containing a contacting medium.Type: GrantFiled: September 21, 1999Date of Patent: July 17, 2001Assignee: DuPont Pharmaceuticals CompanyInventors: David J. Damphousse, Mikhail Kagan
-
Patent number: 6254852Abstract: Targeted ultrasound contrast agents are described. The contrast agents are porous particles of an inorganic material containing an entrapped gas or liquid and having an average particle diameter of about 0.05 to 500 microns. The outer surfaces of the particles incorporate a targeting ligand to target delivery of the contrast agent.Type: GrantFiled: July 16, 1999Date of Patent: July 3, 2001Assignee: Dupont Pharmaceuticals CompanyInventors: Joseph L Glajch, Alan P. Carpenter, Jr., Edward H. Cheesman
-
Patent number: 6254552Abstract: An intra-coronary radiation devices containing Ce-144 or Ru-106 deposited onto a wire and coated with a biocompatible material and methods of making and using the same.Type: GrantFiled: October 1, 1998Date of Patent: July 3, 2001Assignee: E.I. du Pont de Nemours and CompanyInventors: Robert E. Lewis, Prahlad R. Singh, Gerald P. Tercho, Paul R. Walsh
-
Patent number: 6251364Abstract: This invention relates to novel radiopharmaceuticals comprised of highly functionalized pyridine ligated technetium-99m labeled HYNIC-biomolecules that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy. The invention also provides methods of use of the radiopharmaceuticals as imaging agents for the diagnosis of cardiovascular disorders such as thromboembolic disease or atherosclerosis, infectious disease and cancer.Type: GrantFiled: March 29, 1999Date of Patent: June 26, 2001Assignee: DuPont Pharmaceuticals CompanyInventor: Shuang Liu
-
Patent number: 6214847Abstract: The present invention relates to processes for the synthesis of a crystalline polymorph of 10,10-Bis((2-fluoro-4-pyridinyl)methyl)-9(10H)-Anthracenone in high purity. The product is useful in the synthesis of pharmaceutical compounds for the reduction of cholinergic system dysfunction.Type: GrantFiled: August 11, 1998Date of Patent: April 10, 2001Assignee: Dupont Pharmaceuticals CompanyInventors: Jaan A. Pesti, Joseph M. Fortunak, George F. Huhn, Michael Maurin, Jianguo Yin
-
Patent number: 6187918Abstract: Novel chiral aminoalcohol catalysts and methods for their preparation are provided. The first catalyst is prepared via selective hydrogenation of one of two benzene rings in a precursor. The aminoalcohol promotes the asymmetric addition of organozinc reagents to aldehydes to afford optically active alcohols or their esters. The second catalyst is prepared by selective dialkylation of 3-exo-aminoisoborneol with a 2-haloethyl ether. The aminoalcohol promotes the addition of organozinc reagents to aliphatic aldehydes containing a &bgr;-branch with greatly enhanced enantioselectivity relative to DAIB.Type: GrantFiled: March 10, 2000Date of Patent: February 13, 2001Assignee: DuPont Pharmaceuticals CompanyInventor: William A. Nugent